Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives
- Conditions
- Parkinson Disease
- Registration Number
- NCT01089270
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Brief Summary
Parkinson Disease is one of the most common neurodegenerative illnesses. First degree relatives of Parkinson patient are in high risk for developing the disease. We will try to detect early changes in brain metabolism before the appearance of Parkinson symptoms.
Participants: first degree relatives of diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes.
The examination results will be given to the participants by a doctor from the neurology department.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- healthy first degree relatives of diagnosed Parkinson patients
Exclusion Criteria
- patients unable to understand and sign an informed consent
- minors
- people with psychiatric disorders or a history of major head trauma
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel